Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))
Compound class:
Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (PMDA (Japan, 2012), EMA & FDA (2018)) |
International Nonproprietary Names | |
INN number | INN |
9374 | mogamulizumab |
Synonyms |
KW-0761 | mogamulizumab-kpkc | Poteligeo® |
Database Links | |
Specialist databases | |
GPCRdb Ligand | mogamulizumab |
IMGT/mAb-DB | 366 |
Other databases | |
GtoPdb PubChem SID | 178103091 |
PubChem SID | 178103091 |
Search PubMed clinical trials | mogamulizumab |
Search PubMed titles | mogamulizumab |
Search PubMed titles/abstracts | mogamulizumab |
Wikipedia | Mogamulizumab |